Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
This whitepaper discusses cleaning of affinity resins intended for use in the purification of monoclonal antibodies and antibody fragments.
This application note examines these aspects of using sodium hydroxide as a cleaning and sanitizing agent.
A demonstration of the long‑term chromatographic performance of MabSelect PrismA during repeated purification cycles using 0.5 M NaOH for CIP.
This application note demonstrates the binding capacity of MabSelect PrismA in comparison with its predecessor products for both polyclonal and monoclonal antibodies.
Although change may be intimidating, disruptive innovation allows manufacturers to achieve increased efficiency and quality. Several drivers affect how the appropriate facility design and unit operations for a process are selected, making it imperative to properly evaluate each option.
Joe Principe, Vice President of Strategic Partnerships, Patheon, discusses the new set of “must-haves” that are emerging from the increased need for flexibility in outsourced manufacturing partnerships.
Single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity.
Pharmaceutical manufacturer and developer, Penn Pharma, has confirmed that its new contained manufacturing facility for producing highly potent products is on track for opening Q1 2013 at an exclusive event held at the British Embassy, Madrid during ICSE.
Piramal Pharma Solutions (PPS) is pleased to welcome Ash Stevens LLC as a part of the Piramal Group. Leveraging five decades of Ash Stevens’s operational experience and technical expertise, Piramal’s service offering now includes High Potency API (HPAPI) development and manufacturing capabilities. Located in Riverview, USA, our state-of the-art FDA licensed cGMP facility offers a full range of scale and containment options for high potency API manufacturing.
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd with a vast network of development and manufacturing facilities located in North America, Europe and Asia.
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd., having a vast network of development and manufacturing facilities located in North America, Europe and Asia.
